The multivariate prognostic index and nuclear DNA content are independent prognostic factors in primary breast cancer patients

Wiley - Tập 10 Số 1 - Trang 56-61 - 1989
J.C. van der Linden1,2, J. Lindeman1, Jan P. A. Baak2, Coby Meijer2, Chester J. Herman3
1Department of Pathology, Delft, The Netherlands
2Pathologic Institute of the Free University Hospital, Amsterdam, The Netherlands
3Department of Pathology, Loyola University, Maywood, Illinois

Tóm tắt

AbstractThe predictive value of a previously described Multivariate Prognostic Index (which incorporates weighted values of the mitotic activity index, tumor size, and the axillary lymph node status), and the nuclear DNA content (DNA) was evaluated in 156 patients with primary invasive ductal breast cancer, diagnosed between 1980 and 1983. The results were analysed with respect to the occurrence of distant recurrence and survival of the patients after at least 3 yr of follow‐up (range 36–73 months; median 44 months).Known prognostic factors such as lymph node status, tumor size, and the mitotic activity index correlated independently with distant recurrence. Furthermore, in respect to survival, the investigated prognostic factors (except DNA content) were significantly correlated.The results indicate that the predictive value of the Multivariate Prognostic Index (MPI) is stronger (P < 0.001) than of the nuclear DNA content (P < 0.005) with respect to distant recurrence.In a Cox multivariate regression analysis DNA ploidy turned out to be an independent prognostic factor once the MPI was selected. Furthermore, in Cox's analysis, DNA ploidy was the fourth selected variable after lymph node status, mitotic activity index, and tumor size in individual parameter analysis. The results of this study indicate that, with respect to breast cancer screening programs, it seems worthwhile to integrate morphometric features, the MPI, and DNA ploidy in a new prognostic model.

Từ khóa


Tài liệu tham khảo

10.1093/ajcp/78.6.806

10.1002/1097-0142(19850715)56:2<374::AID-CNCR2820560229>3.0.CO;2-9

10.1136/jcp.41.1.21

BonadonnaG RossiA ValagussaP Adjuvant CMF chemotherapy in operable breast cancer: Ten years later.Lancet i:976–977 1985.

10.1002/cyto.990080217

Campell H, 1980, Cancer mortality in Europe. Site‐specific patterns and trends 1955–1974, World Health Stat Q, 33, 241

Dixon WJ, 1983, BMDP statistical software

10.1002/1097-0142(19840201)53:3 <712::AID-CNCR2820531320>3.0.CO;2-I

Hahnel R, 1982, Endocrine Relations in Breast Cancer, 107

10.1177/31.11.6619538

10.1002/cyto.990060409

Herman CJ, 1984, Quantitative cytologic and histologic techniques to assist in cancer evaluation, Methods Achiev Exp Pathol, 11, 73

Herman CJ, 1987, Recent progress in clinical quantitative cytology, Arch Pathol Lab Med, 111, 505

10.1038/bjc.1987.258

10.1136/jcp.40.3.302

10.1136/jcp.39.6.603

McGuire WL, 1985, Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients, J Cancer Inst, 75, 405

McGuireWL MeierJS BarlogieB KuteTE Impact of flow cytometry on predicting recurrence and survival in breast cancer patients.Breast Cancer Res Treat117–128 1985.

10.1002/path.1711490202

10.1002/1097-0142(19860215)57:4<808::AID-CNCR2820570421>3.0.CO;2-#

10.1136/jcp.40.12.1432

10.1093/ajcp/89.3.301

1979, WHO: Handbook for reporting results of cancer treatment, 28

Thông tin
Thông tin xuất bản

Wiley

Tập 10 Số 1

56-61

Thông tin tác giả